Indications

• Thrombocytopenia (see Thrombocytopenia, [[Thrombocytopenia]]): FDA-approved in 2008
  • Refractory Aplastic Anemia (see Aplastic Anemia, [[Aplastic Anemia]]): FDA-approved for this indication in 2/14
  • Thrombocytopenia Associated with Cirrhosis Due to Hepatitis C (see End-Stage Liver Disease, [[End-Stage Liver Disease]])
  • Immune Thrombocytopenic Purpura (ITP) (see Immune Thrombocytopenic Purpura, [[Immune Thrombocytopenic Purpura]])

---

Pharmacology

• Small Molecule Agonist of Thrombopoetin Receptor (cMpl): increases platelet production

---

Administration

• xxxx

---

Adverse Effects

Cardiovascular Adverse Effects

• Orthostatic Hypotension (see Hypotension, [[Hypotension]])

Dermatologic Adverse Effects

• Alopecia (see Alopecia, [[Alopecia]])
• Pruritus (see Pruritus, [[Pruritus]])
• Rash

Hematologic Adverse Effects

• Bone Marrow Reticulin Deposition
• Hemorrhage
• Increased Risk of Hematologic Malignancy
• Thrombosis/Thromboembolism (see Hypercoagulable States, [[Hypercoagulable States]])
• Worsening Thrombocytopenia After Eltrombopag Discontinuation

Gastrointestinal/Hepatic Adverse Effects

• Abdominal Pain (see Abdominal Pain, [[Abdominal Pain]])
• Diarrhea (see Diarrhea, [[Diarrhea]])
• Hepatotoxicity/Hepatic Decompensation: when used in patients with hepatitis C
• Nausea/Vomiting (see Nausea and Vomiting, [[Nausea and Vomiting]])

Neurologic Adverse Effects

• Asthenia (see Asthenia, [[Asthenia]])
• Dizziness (see Dizziness, [[Dizziness]])
• Headache (see Headache, [[Headache]])
• Insomnia (see Insomnia, [[Insomnia]])
• Parasthesias (see Parasthesias, [[Parasthesias]])

Otolaryngologic Adverse Effects

• Oropharyngeal Pain
• Rhinorrhea
• Upper Respiratory Infection
• Xerostomia

Rheumatologic Adverse Effects

• Myalgias (see Myalgias, [[Myalgias]])
• Peripheral Edema (see Peripheral Edema, [[Peripheral Edema]])

Other Adverse Effects

• Cataracts (see Cataracts, [[Cataracts]])
• Cough (see Cough, [[Cough]])
• Fever (see Fever, [[Fever]])

---

References

• xxxx